Six versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Lancet 2019; 393: 2599–2612.

Published: 2nd September 2019

Authors: Earl HM, Hiller L, Vallier A-L, Loi S, McAdam K, Hughes-Davies L et al.

Conclusion

There was no advantage for one year compared to six months of trastuzumab in this study that included over four thousand women: after median 5.4 years, disease-free survival was 89.4 versus 89.8 per cent, respectively.

Pubmed Link

Your comments

0 Comments